These findings highlight PKMYT1 as a potential prognostic marker and therapeutic target, suggesting that its inhibition could serve as a strategy to fight subpopulations of aggressive and chemoresistant cells in NSCLC. This evidence concerns the gene PKMYT1 and non-small cell lung carcinoma.